Cargando…
Efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty: A meta-analysis of randomized controlled trials
BACKGROUND: Risedronate is widely used in the therapy of osteoporosis and other metabolic bone diseases. This meta-analysis was aimed to assess whether administration risedronate could increase the bone mineral density (BMD) in patients undergoing primary total hip arthroplasty (THA). METHODS: Elect...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320077/ https://www.ncbi.nlm.nih.gov/pubmed/30572438 http://dx.doi.org/10.1097/MD.0000000000013346 |
_version_ | 1783385165476659200 |
---|---|
author | Su, Jing Wei, Yi Li, Xiao Ming Diao, Yan-Ping Liu, Huai-Gang Zhang, Liang |
author_facet | Su, Jing Wei, Yi Li, Xiao Ming Diao, Yan-Ping Liu, Huai-Gang Zhang, Liang |
author_sort | Su, Jing |
collection | PubMed |
description | BACKGROUND: Risedronate is widely used in the therapy of osteoporosis and other metabolic bone diseases. This meta-analysis was aimed to assess whether administration risedronate could increase the bone mineral density (BMD) in patients undergoing primary total hip arthroplasty (THA). METHODS: Electronic databases: PubMed, EMBASE, Web of Science, Cochrane Library, and Chinese Wanfang database were searched for all relevant studies. Inclusion criterion was that patients prepared for THA and use risedronate as intervention group and placebo as control group. BMD change in Gruen zone 1 and 7 were primary outcomes. Meta-analysis was performed using Stata 12.0 software. RESULTS: Six RCTs were finally included in this meta-analysis. Compared with control group, risedronate has a beneficial role in increasing BMD in Gruzen 1, 2 6, and 7 at 3 months (P < .05). Oral risedronate has a beneficial role in preservation of BMD in all of the Gruen zones at 6 and 12 months (P < .05). Moreover, oral risedronate could significantly increase the Harris hip scores and bone alkaline phosphatase than control group (P < .05). CONCLUSION: Oral risedronate has an effect on the preservation of periprosthetic BMD in proximal regions (Gruen zone 1, 2, 3, and 7) at 3 months and all of the regions at 6 and 12 months after THA. |
format | Online Article Text |
id | pubmed-6320077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-63200772019-01-14 Efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty: A meta-analysis of randomized controlled trials Su, Jing Wei, Yi Li, Xiao Ming Diao, Yan-Ping Liu, Huai-Gang Zhang, Liang Medicine (Baltimore) Research Article BACKGROUND: Risedronate is widely used in the therapy of osteoporosis and other metabolic bone diseases. This meta-analysis was aimed to assess whether administration risedronate could increase the bone mineral density (BMD) in patients undergoing primary total hip arthroplasty (THA). METHODS: Electronic databases: PubMed, EMBASE, Web of Science, Cochrane Library, and Chinese Wanfang database were searched for all relevant studies. Inclusion criterion was that patients prepared for THA and use risedronate as intervention group and placebo as control group. BMD change in Gruen zone 1 and 7 were primary outcomes. Meta-analysis was performed using Stata 12.0 software. RESULTS: Six RCTs were finally included in this meta-analysis. Compared with control group, risedronate has a beneficial role in increasing BMD in Gruzen 1, 2 6, and 7 at 3 months (P < .05). Oral risedronate has a beneficial role in preservation of BMD in all of the Gruen zones at 6 and 12 months (P < .05). Moreover, oral risedronate could significantly increase the Harris hip scores and bone alkaline phosphatase than control group (P < .05). CONCLUSION: Oral risedronate has an effect on the preservation of periprosthetic BMD in proximal regions (Gruen zone 1, 2, 3, and 7) at 3 months and all of the regions at 6 and 12 months after THA. Wolters Kluwer Health 2018-12-21 /pmc/articles/PMC6320077/ /pubmed/30572438 http://dx.doi.org/10.1097/MD.0000000000013346 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Research Article Su, Jing Wei, Yi Li, Xiao Ming Diao, Yan-Ping Liu, Huai-Gang Zhang, Liang Efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty: A meta-analysis of randomized controlled trials |
title | Efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty: A meta-analysis of randomized controlled trials |
title_full | Efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty: A meta-analysis of randomized controlled trials |
title_fullStr | Efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty: A meta-analysis of randomized controlled trials |
title_full_unstemmed | Efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty: A meta-analysis of randomized controlled trials |
title_short | Efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty: A meta-analysis of randomized controlled trials |
title_sort | efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty: a meta-analysis of randomized controlled trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320077/ https://www.ncbi.nlm.nih.gov/pubmed/30572438 http://dx.doi.org/10.1097/MD.0000000000013346 |
work_keys_str_mv | AT sujing efficacyofrisedronateinimprovingbonemineraldensityinpatientsundergoingtotalhiparthroplastyametaanalysisofrandomizedcontrolledtrials AT weiyi efficacyofrisedronateinimprovingbonemineraldensityinpatientsundergoingtotalhiparthroplastyametaanalysisofrandomizedcontrolledtrials AT lixiaoming efficacyofrisedronateinimprovingbonemineraldensityinpatientsundergoingtotalhiparthroplastyametaanalysisofrandomizedcontrolledtrials AT diaoyanping efficacyofrisedronateinimprovingbonemineraldensityinpatientsundergoingtotalhiparthroplastyametaanalysisofrandomizedcontrolledtrials AT liuhuaigang efficacyofrisedronateinimprovingbonemineraldensityinpatientsundergoingtotalhiparthroplastyametaanalysisofrandomizedcontrolledtrials AT zhangliang efficacyofrisedronateinimprovingbonemineraldensityinpatientsundergoingtotalhiparthroplastyametaanalysisofrandomizedcontrolledtrials |